PLX Protalix BioTherapeutics, Inc.

0.43
+0.02  (6.12%)
Previous Close 0.41
Open 0.41
Price To book 0.00
Market Cap 42.92M
Shares 99,821,000
Volume 1,329,836
Short Ratio 0.11
Av. Daily Volume 2,055,820

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing commenced October 2016. 1-year data due mid-2018.
PRX-102
Fabry disease
Phase 2 interim data released January 3, 2017. Full data due 1Q 2017.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 trial initiation announced November 30, 2016. Data due 2H 2017.
OPRX-106
Ulcerative Colitis

Latest News

  1. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl
  2. Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017
  3. Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
  4. Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  5. Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  6. Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis
  7. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
  8. Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
  9. Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data
  10. 7 Key FDA Decisions and Catalysts Expected in January and February
  11. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
  12. Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  13. Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund
  14. Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis
  15. Blog Coverage Protalix Receives Letter Intending Purchase of Alfataliglicerase to Treat Gaucher Patients in Brazil
  16. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
  17. Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  18. Alexion, Ophthotech Don’t Escape Tuesday’s 52-Week Low Club
  19. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F
  20. FitBit, Teva Slide into Monday’s 52-Week Low Club

SEC Filings

  1. 8-K - Current report 17515701
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17503928
  3. 8-K - Current report 17500355
  4. 8-K - Current report 162069663
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 162069132
  6. 8-K - Current report 162050291
  7. 8-K - Current report 162039961
  8. 8-K - Current report 162029436
  9. 8-K - Current report 162024038
  10. 8-K - Current report 162013414